oMeds
All answers
Answer · metabolic

Stubborn weight gain with no diet change — what is the first oMeds step?

Short answer

Weight gain is routed by metabolic and hormonal context. GLP-1 (semaglutide/tirzepatide) for BMI-eligible candidates with insulin resistance signals; TRT or BHRT when hormone biomarkers match; Lipo-B for adjunct metabolic support.

Reviewed by Dr. Laura PurdyMay 29, 2026

Full answer

Weight gain rarely has a single driver. Provider review reads fasting insulin, A1C, lipids, total/free testosterone, estradiol, TSH, and cortisol context before initiating any pathway. BMI-eligible candidates with insulin resistance or weight-related comorbidity are routed to GLP-1 pathways (semaglutide or tirzepatide); titration and side-effect review happen on the recalibration cadence. Men with confirmed low testosterone and central adiposity are evaluated for Testosterone Optimization in parallel. Women in perimenopause with matching biomarkers are evaluated for BHRT. Lipo-B is an adjunct, never a primary pathway. Every plan is synchronous-video reviewed.

Educational. Not a substitute for individualized provider review.

References & sources
  • Glp1 Semaglutide pathway — Primary source · oMeds
  • Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29